Repurposing existing drugs for COVID-19: an endocrinology perspective.
Flavio Adsuara CadegianiPublished in: BMC endocrine disorders (2020)
While dexamethasone may reduce mortality in severely ill patients with COVID-19, in the absence of evidence of any specific drug for mild-to-moderate COVID-19, researchers should consider testing existing drugs due to their favorable safety, familiarity, and cost profile. However, except for dexamethasone in severe COVID-19, drug treatments for COVID-19 patients must be restricted to clinical research studies until efficacy has been extensively proven, with favorable outcomes in terms of reduction in hospitalization, mechanical ventilation, and death.
Keyphrases
- sars cov
- coronavirus disease
- mechanical ventilation
- drug induced
- low dose
- acute respiratory distress syndrome
- respiratory syndrome coronavirus
- intensive care unit
- high dose
- multidrug resistant
- cardiovascular disease
- cardiovascular events
- adverse drug
- emergency department
- respiratory failure
- skeletal muscle
- insulin resistance
- case control